Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:focusArea |
gptkb:cancer
oral anticancer agents |
| gptkbp:founded |
1963
|
| gptkbp:headquarters_location |
gptkb:Tokyo
|
| https://www.w3.org/2000/01/rdf-schema#label |
Taiho Pharmaceutical
|
| gptkbp:industry |
gptkb:allergy
immunology oncology pharmaceuticals |
| gptkbp:keyPerson |
gptkb:Masayuki_Kobayashi
|
| gptkbp:numberOfEmployees |
over 1,500
|
| gptkbp:parentCompany |
gptkb:Otsuka_Holdings
|
| gptkbp:product |
gptkb:Abraxane
gptkb:Teysuno gptkb:Lonsurf |
| gptkbp:regionServed |
worldwide
|
| gptkbp:stockExchange |
not publicly traded
|
| gptkbp:subsidiary |
gptkb:Otsuka_Holdings
|
| gptkbp:website |
https://www.taiho.co.jp/english/
|
| gptkbp:bfsParent |
gptkb:Otsuka_Pharmaceutical_Co.
gptkb:Otsuka_Holdings |
| gptkbp:bfsLayer |
6
|